Strategic Partnership Potential The recent partnership with Medigroup Services Corp highlights Organogenesis' commitment to collaborating with industry leaders to provide top-quality wound care solutions, presenting an opportunity to explore similar strategic partnerships with other healthcare organizations.
Product Development Opportunity The launch of the development program update for ReNu demonstrates Organogenesis' focus on innovation in regenerative products, creating a potential sales opportunity for offering cutting-edge solutions to healthcare professionals seeking advanced treatment options for knee osteoarthritis.
Investment and Expansion Prospects Securing an investment from the Swiss National Bank showcases financial stability, indicating a potential for further expansion and growth opportunities for Organogenesis, presenting an attractive proposition for investment firms and partners looking to engage with a financially healthy company.
Market Penetration Possibilities The launch of PuraPly Antimicrobial Wound Matrix underscores Organogenesis' commitment to introducing innovative wound care solutions, creating an opening to explore new markets and expand customer base by showcasing the efficacy of their products in reducing bacterial contamination and supporting wound healing.
Enhanced Board Expertise Advantage Appointing industry experts like Michele Korfin and Gilberto Quintero to its Board of Directors adds significant value to Organogenesis by leveraging their expertise, presenting an opportunity to leverage the credibility of the board members to attract potential partners and investors who seek to collaborate with a company backed by experienced professionals.
5K
$1B
10K$1B
1$10M
93K$1B
103K$1B
3.7K$1B
66K$1B
3.4K$100M$1BOrganogenesis uses 8 technology products and services including Azure Analysis Services, Microsoft Power BI, Drupal, and more. Explore Organogenesis's tech stack below.
| Organogenesis Email Formats | Percentage |
| FLast@organo.com | 99% |
| FMiddleLast@organo.com | 1% |
| First@organogenesis.com | 53% |
| FLast@organogenesis.com | 44% |
| First.Last@organogenesis.com | 2% |
| First.MiddleLast@organogenesis.com | 1% |
Biotechnology ResearchMassachusetts, United States501-1000 Employees
Organogenesis™ is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.
Company Overview
Media & News
Funding & FinancialsOrganogenesis has raised a total of $200M of funding over 7 rounds. Their latest funding round was raised on Aug 09, 2021 in the amount of $200M.
Organogenesis's revenue is in the range of $100M$1B
Funding & FinancialsOrganogenesis has raised a total of $200M of funding over 7 rounds. Their latest funding round was raised on Aug 09, 2021 in the amount of $200M.
Organogenesis's revenue is in the range of $100M$1B
1-888-653-2347 
support@leadiq.com